Avemar®: Fermented Wheat Germ Extract (FWGE)

Evidence-Based Supplement for Oncology Patients

 

Avemar is a nutraceutical that increases the positive effects of clinical oncological therapies.

Cancer patients who combine chemotherapy, immunotherapy, radiotherapy with Avemar will benefit from:

Avemar has been administered worldwide as a complementary cancer treatment product since 1998 for its anti-metastatic and immunomodulatory benefits across all cancers. Its use has been proven to make patients stronger, making them able to take more chemotherapy and tolerate treatment better.

Over 100 independent studies, including 10 human clinical trials since 1998, have demonstrated the safety and efficacy of Avemar, including extensive research made by Nobel Laureate Dr. James D. Watson at Cold Spring Harbor University in the USA.

Based on the idea to supplement cancer patients with benzoquinones by Hungarian Nobel laureate Dr. Albert Szent-Györgyi, Avemar was created by Hungarian biochemist Dr. Máté Hidvégi from fermented wheat germ extract.

Avemar has unique small molecules and proteins which are together responsible for its effects. 2 of these molecules have been identified and patented for possible stand-alone use in oncology. Currently, only Avemar, the finished product, offers patients these molecules in a combined form.

Avemar is a dietary supplement on most markets. Acknowledging its proven benefits, it is registered as a food for the special medical purposes of cancer patients in Portugal and Hungary. It is exclusively manufactured by Biropharma in Hungary.

Patients usually take 1 drink powder or 10 tablets daily, continuously from the first moment of diagnosis until full recovery. Effects will be visible after 8-10 weeks of continuous consumption. Side effects are mild gastroenteric, if any.